Merck & Co., Inc. is 7.6x more valuable than ALNYLAM PHARMACEUTICALS, INC. by market capitalization ($294.13 B vs $38.52 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | ALNY | MRK |
|---|---|---|
| Market cap | $38.52 B | $294.13 B |
| US-listed rank | #396 | #44 |
| Revenue (latest FY) | $3.71B | $65.01B |
| Net income (latest FY) | $313.75M | $18.25B |
| Net margin | 8.4% | 28.1% |
| P/E (trailing FY) | 122.8 | 16.1 |
| SEC filings | 1,651 | 996 |
Merck & Co., Inc. is 7.6x more valuable than ALNYLAM PHARMACEUTICALS, INC. by market capitalization ($294.13 B vs $38.52 B).
In their latest fiscal years, ALNYLAM PHARMACEUTICALS, INC. reported $3.71B in revenue while Merck & Co., Inc. reported $65.01B.
Full pages: ALNYLAM PHARMACEUTICALS, INC. and Merck & Co., Inc., or browse the full rankings.